As a country with a high burden of dengue, the approval of a vaccine for India that is targeted at four types of the virus marks a public health milestone. QDENGA, the vaccine from Takeda Biopharmaceuticals India, is the first to get market authorisation from the Drug Controller General for the 4 to 60 year age group and is designed to provide a defence against dengue through a two-shot regimen, with a claimed efficacy of 80.2% on infection and 90.4% on hospitalisation. The combination of antibody defences against the four types of dengue viruses through live attenuated, or weakened, viruses, regardless of previous infection, is aimed at comprehensive protection, and the outcomes of the vaccination will be closely watched........

© Free Press Journal